Trodelvy (Sacituzumab govitecan-hziy) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate used for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease.
Dosage: The recommended dose of Trodelvy is 10 mg/kg, which should be administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles. Continue treatment until the disease is progressive or unacceptable toxicity occurs. Avoid administering this medication at doses higher than 10 mg/kg. Administer it as an intravenous infusion only. Do not administer as an intravenous push or bolus.
Side Effects: The most commonly reported trodelvy side effects (incidence >25%) include:
- decreased appetite
- abdominal pain
Warnings and Precautions:
- Use of trodelvy breast cancer drug is restricted in patients who have experienced a severe hypersensitivity reaction to this medication.
- Observe patients closely for infusion-related reactions during each trodelvy 180 mg infusion and for at least 30 minutes after completion of each infusion.
- The respective patients who are on Sacituzumab govitecan-hziy injection treatment and with reduced UGT1A1 activity should be monitored for severe neutropenia.
- The mechanism of action suggests that trodelvy drug can be responsible for causing teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman.
- Women should not breastfeed during treatment and for one month following the last trodelvy dose.
- Patients at risk of neutropenia must immediately contact their health specialist if they experience fever, chills, or other signs of infection